| 词条 | BioMérieux |
| 释义 |
| name = bioMérieux | logo = BioMérieux logo.svg | logo_size = 180px | type = Société Anonyme | industry = Biotechnology | products = in vitro diagnostics | traded_as = {{Euronext |BIM}} | foundation = {{start date and age|1963}} | founder = {{Dr}} Alain Mérieux | key_people = Alexandre Mérieux (CEO){{Dr}} Marcel Mérieux, {{Dr}} Charles Mérieux | location = Marcy-l'Étoile, France | area_served = Worldwide | revenue = €2,29 billion (2017) | num_employees = 10 400 (2017) | homepage = {{URL|http://www.biomerieux.com}} }}bioMérieux ({{Euronext|BIM}}) is a multinational biotechnology company founded and headquartered in France. bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors.[1] bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.[2] bioMérieux is listed on the NYSE Euronext Paris stock exchange (BIM – ISIN: FR0010096479).[3] RevenuebioMérieux had revenues of €2.103 billion as of 2016 with 90% of sales occurring outside France.[4] In year 2017, the company increased its annual revenue to €2.288 billion.[5] [https://www.biomerieux.com/en/annual-report 2017 Annual Report] HistoryMarcel Mérieux, former assistant to Louis Pasteur founded in 1897 the Mérieux Biological Institute which was later to become Institut Mérieux. In 1963 Alain Mérieux founds BD Mérieux, of which he assumes total control of in 1973. BD Mérieux would later become bioMérieux. The company expands its services and offerings through product development, acquisitions and partnerships:
References1. ^https://www.euronext.com/en/products/equities/FR0010096479-XPAR/company-information 2. ^https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=23790762 3. ^https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=23790762 4. ^http://www.biomerieux.com/en/biomerieux-2016-financial-results 5. ^http://www.biomerieux-finance.com/sites/investord7/files/ddr_2017_gb_vdef.pdf 6. ^http://www.referenceforbusiness.com/history2/13/bioM-rieux-S-A.html 7. ^http://www.referenceforbusiness.com/history2/13/bioM-rieux-S-A.html 8. ^https://www.akzonobel.com/for-media/media-releases-and-features/akzo-nobel-transfers-organon-teknikas-diagnostics-business 9. ^https://scrip.pharmaintelligence.informa.com/deals/200610151 10. ^https://mergr.com/biomerieux-s.a.-acquires-btf-pty. 11. ^https://www.reuters.com/article/biomerieux/biomerieux-buys-u-s-microbiology-firm-idINL863440920081208 12. ^http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=272481 13. ^http://www.qualityassurancemag.com/article/qa-052011-biomerieux-acquires-aes-laboratoire/ 14. ^http://www.quanterix.com/resources/press-releases/biomerieux-and-quanterix-sign-strategic-partnership-ultrasensitive-and 15. ^https://www.genomeweb.com/pcrsample-prep/biomerieux-finalizes-biofire-diagnostics-acquisition 16. ^https://www.reuters.com/article/biomerieux-biofire/biomerieux-buys-diagnostics-rival-biofire-for-450-mln-idUSL6N0H014H20130904 17. ^http://www.clpmag.com/2017/06/biofire-opens-center-molecular-diagnostics/ 18. ^https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=23790762 19. ^https://invivo.pharmaintelligence.informa.com/IV002374/bioMerieux-a-FamilyOwned-French-Firm-Finally-Goes-Public External links
5 : Biotechnology companies of France|Companies listed on the Euronext exchanges|HIV/AIDS in Iran|Biotechnology companies established in 1963|1963 establishments in France |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。